A Dose-Escalation Study to Assess the Safety and Tolerability of LX214 Ophthalmic Solution in Healthy Volunteers, Followed by an Open-Label Evaluation of LX214 in Patients With Keratoconjunctivitis Sicca (KCS)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Lux Biosciences, Inc.
Age
18–55
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
No systemic disease as determined by a physical examination, clinical laboratory evaluation, and an ECG
Schirmer's I Test ≥ 10mm/5 minutes with anesthesia
Corrected Snellen acuity of 20/40 or better in both eyes
You may not be if
Subjects diagnosed with any ocular disease other than refraction error
Subjects with intraocular pressure \>21 mmHg
Use of a contact lens within 7 days prior to administration of the first dose
Subjects with history of ocular surgery
Subjects with a history of laser refractive surgery
Clareo Health | A Dose-Escalation Study to Assess the Safety and Tolerability of LX214 Ophthalmic Solution in Healthy Volunteers, Followed by an Open-Label Evaluation of LX214 in Patients With Keratoconjunctivitis Sicca (KCS)
